CoreCap Advisors LLC Acquires 35,480 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

CoreCap Advisors LLC lifted its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 8,870.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,880 shares of the biopharmaceutical company's stock after acquiring an additional 35,480 shares during the quarter. CoreCap Advisors LLC's holdings in Catalyst Pharmaceuticals were worth $749,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Castlekeep Investment Advisors LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter valued at about $37,494,000. Bank of America Corp DE raised its stake in shares of Catalyst Pharmaceuticals by 139.5% in the 4th quarter. Bank of America Corp DE now owns 1,568,791 shares of the biopharmaceutical company's stock valued at $32,741,000 after purchasing an additional 913,843 shares in the last quarter. abrdn plc acquired a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter valued at about $10,115,000. Arrowstreet Capital Limited Partnership raised its stake in shares of Catalyst Pharmaceuticals by 131.4% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 698,152 shares of the biopharmaceutical company's stock valued at $14,570,000 after purchasing an additional 396,506 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Catalyst Pharmaceuticals by 4.9% in the 4th quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company's stock valued at $175,957,000 after purchasing an additional 390,116 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company's stock.

Insider Activity at Catalyst Pharmaceuticals

In related news, insider Brian Elsbernd sold 62,975 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the transaction, the insider now owns 188,564 shares in the company, valued at $4,333,200.72. This trade represents a 25.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gary Ingenito sold 44,904 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the sale, the insider now owns 68,873 shares of the company's stock, valued at $1,521,404.57. The trade was a 39.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 10.40% of the company's stock.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ:CPRX traded up $0.46 during trading hours on Thursday, hitting $23.86. The stock had a trading volume of 241,938 shares, compared to its average volume of 1,106,472. The stock's fifty day simple moving average is $23.10 and its 200 day simple moving average is $22.44. Catalyst Pharmaceuticals, Inc. has a 1-year low of $14.75 and a 1-year high of $26.16. The firm has a market capitalization of $2.91 billion, a price-to-earnings ratio of 20.20, a PEG ratio of 3.31 and a beta of 0.70.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Stephens restated an "overweight" rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. HC Wainwright restated a "buy" rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Robert W. Baird raised their target price on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a report on Monday, March 3rd. Baird R W raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. Finally, StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $32.29.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.